| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Purity: ≥98%
TAK-220 (TAK220), a novel 1,4-disubstituted piperidine/piperazine, is a potent, selective and orally bioavailable CCR5 antagonist with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively. It shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC90s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.
| ln Vitro |
TAK-220 is a selective CCR5 antagonist that, in CHO cells, shows IC50s of 3.5 nM and 1.4 nM, respectively, inhibiting the binding of RANTES and MIP-1α to CCR5, but not the binding to CCR1, CCR2b, or CCR3. CCR7 or CCR4. TAK-220 (0-1000 nM) inhibits CCR5-mediated Casup>2+ signaling and binds with CCR5 but not RANTES. With an IC50 value of 0.42 nM, TAK-220 inhibits R5 HIV-1 (JR-FL) envelope-mediated membrane fusion, while it has no effect on X4 HIV-1 (HXB2) envelope-mediated membrane fusion. With EC50 values of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), 0.55 nM (HIV-1 HHA), and EC90 values of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM in PBMC of (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) [1]. Moreover, TAK-220 selectively inhibits HIV-1. With IC50 values of 3.12 nM against HIV-1 R5-08, 13.47 nM against HIV-1 R5-06, and 2.26 nM against HIV-1 R5-18, TAK-220 demonstrated strong inhibitory efficacy against R5 isolates. In uninfected PBMC, TAK-220 (>100 nM) is not harmful [2].
|
|---|---|
| References |
[1]. Takashima K, et al. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother. 2005 Aug;49(8):3474-82.
[2]. Tremblay CL, et al. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. Antimicrob Agents Chemother. 2005 Aug;49(8):3483-5 |
| Molecular Formula |
C31H41CLN4O3
|
|---|---|
| Molecular Weight |
553.1352
|
| CAS # |
333994-00-6
|
| Related CAS # |
333994-00-6; 674782-27-5 (TAK-220 HCl)
|
| SMILES |
O=C(C1CCN(C(C)=O)CC1)N(CCCN2CCC(CC3=CC=C(C(N)=O)C=C3)CC2)C4=CC=C(C)C(Cl)=C4
|
| InChi Key |
ASSJTMUEFHUKMJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H41ClN4O3/c1-22-4-9-28(21-29(22)32)36(31(39)27-12-18-35(19-13-27)23(2)37)15-3-14-34-16-10-25(11-17-34)20-24-5-7-26(8-6-24)30(33)38/h4-9,21,25,27H,3,10-20H2,1-2H3,(H2,33,38)
|
| Chemical Name |
1-acetyl-N-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
|
| Synonyms |
TAK220, TAK 220, TAK-220
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~90.39 mM)
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8079 mL | 9.0393 mL | 18.0786 mL | |
| 5 mM | 0.3616 mL | 1.8079 mL | 3.6157 mL | |
| 10 mM | 0.1808 mL | 0.9039 mL | 1.8079 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA